21 results on '"Bonig, Halvard"'
Search Results
2. Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs?
3. A guide to the collection of T-cells by apheresis for ATMP manufacturing—recommendations of the GoCART coalition apheresis working group
4. Automatic generation of alloreactivity-reduced donor lymphocytes and hematopoietic stem cells from the same mobilized apheresis product
5. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
6. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
7. Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization
8. CD3/CD19 Depletion for T-cell Reduction of Allogeneic Transplants: Mostly Efficient, but not Robust
9. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
10. Generation and validation of a formula to calculate hemoglobin loss on a cohort of healthy adults subjected to controlled blood loss
11. Absence of the CXCR4 antagonist EPI-X4 from pharmaceutical human serum albumin preparations
12. Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site
13. ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia
14. PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1
15. The transcription factor TAL1 and miR-17-92 create a regulatory loop in hematopoiesis
16. Donor-intrinsic variables determine mobilization efficiency: analyses from a cohort of sixty twice-mobilized stem cell donors
17. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)
18. CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib
19. Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies
20. A validation protocol and evaluation algorithms to determine compatibility of cell therapy product matrices in microbiological testing
21. Epigenetic Modifications and Chromosome Conformations of the Beta Globin Locus throughout Development
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.